Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN AND AMLODIPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN AND AMLODIPINE.
BENICAR HCT vs TELMISARTAN AND AMLODIPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
Oral: one tablet containing telmisartan 40-80 mg and amlodipine 5-10 mg once daily; maximum dose: telmisartan 80 mg/amlodipine 10 mg daily.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Telmisartan: terminal half-life ~24 hours (range 20-30 hours), supporting once-daily dosing. Amlodipine: terminal half-life ~30-50 hours (mean 35 hours), achieving steady state after 7-8 days; prolonged half-life allows once-daily dosing.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Telmisartan: primarily excreted unchanged in feces (97%) via biliary elimination; renal excretion accounts for <2%. Amlodipine: extensively metabolized in liver; 60% of metabolites excreted renally, 20-25% in feces. Unchanged amlodipine in urine: <10%.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB